Table V.

 Treatment of Patients Included in the Two Cross‐Sectional Surveys (Before and After the Intervention Program)

	1º Survey Before Intervention	2º Survey After Intervention	P Value
Antihypertensive medication (%, 95% CI)
% Patients with pharmacological treatment	98.6 (98.2–99.1)	99.3 (98.9–99.6)	.11
Number of drugs (mean, 95% CI)	1.8 (1.8–1.9)	1.9 (1.8–1.9)	.13
1 Drug	40.0 (38.1–41.9)	37.3 (35.2–39.3)	.02
2 Drugs	40.3 (38.3–42.2)	43.3 (41.2–45.4)
3 Drugs	17.1 (15.6–18.6)	15.8 (14.3–17.3)
≥4 Drugs	2.6 (2.0–3.2)	3.6 (2.8–4.4)
Diuretics	48.6 (46.7–50.6)	48.5 (46.4–50.6)	.95
Thiazide	35.5 (33.6–37.4)	36.0 (34.0–38.0)	.69
Loop	10.6 (9.4–11.8)	9.0 (7.8–10.2)	.08
Spironolactone	1.0 (0.6–1.3)	1.2 (0.7–1.7)	.43
β‐blockers	14.6 (13.2–16.0)	14.4 (13.0–15.9)	.88
ACEI	32.0 (30.1–33.8)	30.8 (28.9–32.8)	.39
ARB	56.2 (54.2–58.1)	61.0 (59.0–63.1)	.0008
Calcium antagonists	21.9 (20.3–23.5)	24.1 (22.3–25.9)	.07
Others	6.9 (5.8–7.7)	6.0 (4.9–6.8)
Lipid lowering drugs (%, 95% CI)
% Patients with pharmacological treatment	59.9 (57.9–61.8)	59.9 (57.9–62.0)	.51
Statins	57.1 (55.1–59.0)	56.7 (54.6–58.8)	.80
Resin/ezetimibe	3.2 (2.5–3.9)	4.0 (3.2–4.8)	.14
Fibrates	2.8 (2.2–3.5)	2.3 (1.6–2.9)	.20
Diabetes treatment (%, 95% CI)
% Patients with pharmacological treatment	86.8 (84.8–88.8)	88.25 (86.2–90.3)	.58
Oral antidiabetics	67.0 (64.3–69.8)	70.2 (67.3–73.1)	.30
1 Drug	69.0 (65.7–72.3)	74.4 (71.1–77.7)
2 Drugs	31.0 (27.7–34.3)	25.6 (22.3–28.9)
Insulin	9.8 (64.3–69.8)	8.0 (6.29–9.72)
Oral antidiabetics + insulin	9.9 (8.18–11.7)	10.1 (8.18–12.0)
Other treatments (%, 95% CI)
Antiplatelet therapy	43.2 (41.2–45.1)	42.9 (40.8–45.0)	.84

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval.